OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Morgan on Treatment Selection in Multiple Myeloma

May 22nd 2020

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 22nd 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Thiel on Protecting Patients and Providers From COVID-19

May 21st 2020

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

Dr. Sznol on the Use of Immunotherapy in Melanoma

May 21st 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

May 21st 2020

Hope S. Rugo, MD, discusses the results of the phase 3 KEYNOTE-522 trial in triple-negative breast cancer (TNBC).

Dr. Smith on Unmet Clinical Needs in Indolent Lymphomas

May 21st 2020

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Dr. Morgan on Treatment Selection in Multiple Myeloma

May 21st 2020

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 21st 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Parikh on the Role of Radiation in HCC

May 21st 2020

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 21st 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 21st 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 21st 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 21st 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Dr. Lewin on the Impact of COVID-19 on Cancer Care

May 20th 2020

Sharyn Lewin, MD, FACS, discusses the impact of the coronavirus disease 2019 (COVID-19) on cancer care.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 20th 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Parikh on the Role of Radiation in HCC

May 20th 2020

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 20th 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Brufsky on the Risk COVID-19 Poses to Patients With Cancer

May 20th 2020

Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 20th 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Subbiah on the Utility of Tivozanib in RCC

May 20th 2020

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.